efmarodocokin alfa

Efmarodocokin alfa is a recombinant fusion protein consisting of human interleukin 22 (IL-22) fused to the Fc portion of human immunoglobulin G4 (IgG4), engineered with a mutation to minimize Fc effector functions. It acts as an agonist of the interleukin 22 receptor, activating the IL-22 signaling pathway. This drug is designed for cell-protective and immunomodulatory effects, particularly targeting epithelial tissues such as those in the gut. Efmarodocokin alfa has been investigated primarily for inflammatory diseases including ulcerative colitis, Crohn's disease, and other conditions involving epithelial barrier dysfunction. The drug was developed by Genentech/Roche and Chugai Pharmaceutical but development has been discontinued for all known indications[1][2][3][4][5].

Other names

efmarodocokin alfa